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Abstract
The variability of eosinophilic infiltrates in eosinophilic esophagitis is not well described. This 
study aimed to determine the distribution of esophageal eosinophilia and the utility of histologic 
cut-points for eosinophilic esophagitis diagnosis in subjects undergoing endoscopy. We performed 
a prospective study of adults undergoing outpatient endoscopy. Research protocol esophageal 
biopsies were obtained from all subjects. Incident cases of eosinophilic esophagitis were 
diagnosed per consensus guidelines. Biopsies were interpreted following a validated protocol, and 
maximum eosinophil counts (eosinophils per high-power field; eos/hpf) were determined. 
Histologic analyses were performed on a per-patient, per-biopsy, and per-hpf basis. There were 
213 patients, yielding 923 esophageal biopsies with 4588 hpfs. Overall, 48 patients (23%), 165 
biopsy fragments (18%), and 449 hpfs (10%) had ≥ 15 eos/hpf; most subjects had no or low levels 
of eosinophils. In the eosinophilic esophagitis cases, 119 biopsy fragments (63%) and 332 hpfs 
(36%) had ≥ 15 eos/hpf. There was a mean 104-fold difference between the lowest and highest hpf 
eosinophil count for the eosinophilic esophagitis patients; 85% of the biopsies from eosinophilic 
esophagitis cases also had at least one hpf with < 15 eos/hpf. The cut-point of 15 eos/hpf had a 
sensitivity of 100% and specificity of 96% for diagnosis of eosinophilic esophagitis. In 
conclusion, most patients have little to no esophageal eosinophilia. In patients with eosinophilic 
esophagitis, there was marked variability in the eosinophil counts by biopsy and by hpf within a 
given biopsy. Additionally, the 15 eos/hpf cut-point was highly sensitive and specific for 
eosinophilic esophagitis. Multiple esophageal biopsies from different locations should be obtained 
to optimize eosinophilic esophagitis diagnosis.
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The human esophagus is lined with a stratified squamous epithelium that is devoid of 
eosinophils under normal conditions. The presence of esophageal eosinophilia has been 
increasingly reported over the last two decades.1-5 While the majority of recent reports focus 
on eosinophilic esophagitis as the cause, esophageal eosinophilia itself is non-specific and 
has a wide different diagnosis.6-9 In addition to eosinophilic esophagitis, the most common 
causes include gastroesophageal reflux disease and proton pump inhibitor-responsive 
esophageal eosinophilia, a condition where esophageal eosinophilia may not be attributed to 
reflux and resolves after proton pump inhibitor treatment.10-13 Additionally, pill esophagitis, 
drug reactions, infections, Crohn’s disease, autoimmune and connective tissue disorders, 
achalasia, graft-versus-host disease, and other conditions have also been associated with 
esophageal eosinophilia.6,7
The spectrum of esophageal eosinophilia in patients presenting for upper endoscopy and 
esophageal biopsy is not well described. In eosinophilic esophagitis in particular, a level of 
15 eosinophils per high power field (eos/hpf) has been adopted as the histologic cut-point in 
diagnostic algorithms,4,6,7 but this value is largely empiric and its appropriateness has never 
been rigorously tested.14 Further, the eosinophilic infiltrate can be patchy and unevenly 
distributed in eosinophilic esophagitis, but the full degree of variability is not well 
described.8,9 These poorly defined parameters impact clinical guidelines, biopsy protocols, 
and histologic analysis.
The aims of this study were to determine the distribution of esophageal eosinophilia in a 
wide range of subjects undergoing endoscopy, describe variability of eosinophil counts in 
patients with eosinophilic esophagitis at the per patient, per biopsy, and per high-power-field 
level, and assess the utility of the 15 eos/hpf cut-point.
Materials and Methods
Patients and esophageal biopsy sources
This was a prospective study at the University of North Carolina from 2009-2012. We 
enrolled consecutive adults from age 18 to 80 years undergoing outpatient 
esophagogastroduodenoscopy who had either dysphagia or symptoms of gastroesophageal 
reflux disease. Patients were excluded if they had a known eosinophilic gastrointestinal 
disorder, including eosinophilic esophagitis, were anticoagulated or having an active GI 
bleed, had known esophageal varices, esophageal cancer, or prior esophageal surgery, had 
medical instability precluding enrollment, or were unable to read or understand the consent 
form. Details of this study design have been previously reported.13
Cases of eosinophilic esophagitis were defined as per consensus guidelines.6,7 Specifically, 
patients were required to have at least one typical symptom of esophageal dysfunction 
(dysphagia, food impaction, or heartburn); at least 15 eos/hpf on esophageal biopsy after an 
8 week proton pump inhibitor trial (20-40 mg twice daily of any of the available agents, 
selected at the discretion of the clinician); and other causes of esophageal eosinophilia 
excluded.6,7 Subjects without eosinophilic esophagitis did not meet these clinical or 
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histologic criteria, but could have other findings or diagnoses. Of note, a non- eosinophilic 
esophagitis subject could have ≥ 15 eos/hpf attributable to a different cause, such as proton 
pump inhibitor-responsive esophageal eosinophilia, reflux, achalasia or esophageal 
dysmotility, infection, etc.7 Samples from the proton pump inhibitor-responsive esophageal 
eosinophilia patients were analyzed after the proton pump inhibitor trial, and were included 
in the group of subjects without eosinophilic esophagitis; all of these proton pump inhibitor-
responsive esophageal eosinophilia subjects were therefore on proton pump inhibitor. All 
eosinophilic esophagitis subjects were also on proton pump inhibitor, as per diagnostic 
guidelines. The other study subjects without eosinophilic esophagitis could be on proton 
pump inhibitor as clinically indicated at the discretion of their referring provider.
During the endoscopy, a total of five research protocol esophageal biopsies were obtained 
(two from the proximal, one from the mid, and two from the distal esophagus) to maximize 
eosinophilic esophagitis diagnostic sensitivity.15 Distal biopsies were obtained 3 cm above 
the gastroesophageal junction, mid esophageal biopsies were obtained 10 cm above the 
gastroesophageal junction, and proximal esophageal biopsies were obtained 15 cm above the 
gastroesophageal junction. Each esophageal biopsy fragment was collected, labelled, 
processed, and embedded into paraffin separately. Concomitant gastric and duodenal 
biopsies were used to exclude eosinophilic gastritis or gastroenteritis. At the discretion of 
the endoscopist, additional clinical biopsies could be taken as needed. The study was 
approved by the University of North Carolina Institutional Review Board, and subjects 
provided informed consent prior to endoscopy.
Histologic analysis
The study pathologists utilized our previously validated protocol to determine eosinophil 
counts and associated findings for each of the biopsy fragments obtained.16,17 In brief, slides 
were deidentified without reference to clinical data or endoscopic findings and then scanned, 
digitized, and viewed with Aperio ImageScope (Aperio Technologies, Vista, CA). For each 
of the five biopsy fragments, five microscopy fields were assessed to determine the 
maximum eosinophil density (eosinophils/mm2 [eos/mm2]). For reporting and in order to 
compare the eosinophil densities to results from other studies, they were converted to 
eosinophil counts (eos/hpf) for a hpf size of 0.24 mm2, the size of an average field as 
reported in the literature.14
The eosinophil infiltration was further examined to determine whether it was patchy 
(defined as localized eosinophilia ≥ 15 eos/hpf in only one hpf in the biopsy) or diffuse 
(eosinophilic inflammation seen in multiple hpfs) throughout the entire biopsy sample, as 
well as whether the eosinophil distribution throughout the mucosa was superficial only, 
basal only, or diffuse (throughout the epithelium). Additionally the presence of eosinophilic 
microabscesses (clusters of ≥ 4 eosinophils), eosinophil degranulation, basal layer 
hyperplasia (when evaluable in properly oriented specimens), spongiosis, and lamina propria 
fibrosis (if adequate subepithelial stroma was present) were recorded as defined in previous 
publications.8,9
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Descriptive statistics were used to summarize characteristics of the study population. 
Histologic findings were analyzed on a per patient, per biopsy, and per hpf basis. For the per 
patient analysis, the maximum eosinophil count found in any specimen from that patient was 
the outcome of interest; for the per biopsy analysis, the maximum eosinophil count from any 
of the hpfs within that biopsy fragment was reported; and for the per hpf analysis, data from 
every hpf were analyzed separately. Histograms representing the distributions of eosinophil 
counts for each of these analyses, both overall and by location of the biopsy fragments 
(distal, mid, or proximal esophagus) were constructed. The hpf analysis was also used to 
determine patchiness of the eosinophilic infiltrate. Specifically, the variation in level of 
esophageal eosinophilia was calculated as the fold-change between the minimum and 
maximum eosinophil count in each set of biopsies. Finally, we calculated the sensitivity, 
specificity, positive predictive value, and negative predictive value of using 15 eos/hpf as 
the histologic cut-point for eosinophilic esophagitis. We also made the same calculations for 
cut-points of 10 and 20 eos/hpf. Statistical analysis was performed using Stata version 9 
(Statacorp, College Station, TX).
Results
Esophageal biopsies were analyzed from 213 patients. The mean age was 49 years (range 
18-79), 48% were male, and 81% were white (Table 1). As expected with the study design, 
dysphagia was the most common symptom (77%) and gastroesophageal reflux disease was 
the most common diagnosis (21%). eosinophilic esophagitis was found in 41 patients (19%), 
proton pump inhibitor-responsive esophageal eosinophilia was seen in 24 (11%), and 
achalasia or other motility disorders were seen in 25 (11%). These 213 patients yielded a 
total of 923 biopsy fragments containing 4588 hpfs that were evaluated in the histologic 
analysis.
Spectrum of esophageal eosinophilia in all subjects undergoing endoscopy
The majority of subjects had low levels or no esophageal eosinophilia noted on per-patient, 
per-biopsy, and per-hpf analyses (Figure 1). A total of 150 patients (70%) had 10 eos/hpf or 
less, 96 (45%) had 0 eos/hpf, and 48 (23%) had ≥ 15 eos/hpf. A total of 739 biopsy 
fragments (80%) had 10 or less eos/hpf, 553 (60%) had 0, and 165 (18%) had ≥ 15. A total 
of 4034 hpfs (88%) had 10 of less eos/hpf, 3358 (73%) had 0, and 449 (10%) had ≥ 15. The 
overall range of the maximum eosinophil counts was from 0 to 466 eos/hpf.
Among all subjects, the mean of the maximum eosinophil counts on the per-patient, per-
biopsy, and per-hpf analyses were 25, 13, and 7 eos/hpf, respectively (Table 2). However, 
the median values were much lower (1.5, 0, and 0 eos/hpf, respectively), indicating that the 
mean values were impacted by the set of patients with very high eosinophil counts. 
Eosinophil degranulation was observed in 33% of patients, 24% of biopsies, and 14% of 
hpfs, and microabscesses were seen in 13%, 7%, and 3%, respectively. In this patient 
population, subepithelial stroma was not routinely noted, being present in only 38% of 
patients and 15% of all esophageal biopsies. Fibrosis of the lamina propria was also not 
common, seen in 8% of patients and 3% of biopsies. Qualitatively, the eosinophilic 
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distribution was diffuse throughout the mucosa (ie no superficial vs basal predominance and 
the inflammation was seen throughout the entire mucosa), but was patchy throughout the 
entire biopsy specimen (ie there were some areas with prominent eosinophilic infiltration, 
but other areas where this was much less pronounced).
Variability of esophageal eosinophilia in subjects with eosinophilic esophagitis
When analyzing those diagnosed with eosinophilic esophagitis (n = 41), despite high 
eosinophil counts at the patient level (mean of the maximum eosinophil count = 108 eos/
hpf) with frequent associated histologic findings (degranulation in 93%, microabscesses in 
59%, basal layer hyperplasia in 66%, spongiosis in 80%, and lamina propria fibrosis in 
27%), there was substantial variability in eosinophil counts on per-biopsy and per-hpf 
analysis (Figure 2). Of the 189 biopsy fragments, 43 (23%) had ≤ 5 eos/hpf, and 119 (63%) 
had ≥ 15 eos/hpf. Of the 932 hpfs, 445 (48%) had ≤ 5 eos/hpf, and 332 (36%) had ≥ 15 eos/
hpf. There were no substantial differences between eosinophil counts and associated 
histologic finding on either the per-biopsy or per-hpf analysis based on the location of the 
sample (Table 3).
With this level of variability, there was a mean 104-fold difference between the lowest and 
highest eosinophil count for the eosinophilic esophagitis patients. While every patient with 
eosinophilic esophagitis had at least one hpf with an eosinophil count of ≥ 15 eos/hpf by 
definition, 85% of the biopsies also had at least one hpf with < 15 eos/hpf. The average of 
the maximum eosinophil counts for all hpfs was 108 eos/hpf (range: 16-466). The average of 
the minimum eosinophil counts for all hpfs was 1 eos/hpf (range 0-11).
Operating characteristics of the eosinophil count and other histologic findings
When the current histologic cut-point of 15 eos/hpf for diagnosis of eosinophilic esophagitis 
was assessed at the per-patient level, it had a sensitivity of 100% (41/41), a specificity of 
96% (165/172), a positive predictive value of 85% (41/48), and a negative predictive value 
of 100% (165/165). Alternative cut-points of 10 or 20 eos/hpf did not perform as well, nor 
did specific histologic findings (Table 4). Though eosinophilic microabscesses and lamina 
propria fibrosis were specific for eosinophilic esophagitis (98% and 97%, respectively), they 
were not sensitive (56% and 27%, respectively). On a per biopsy level, the cut-point of 15 
eos/hpf performed less well, with a sensitivity of 63% (119/189), specificity of 94% 
(688/734), positive predictive value of 70% (46/165), and negative predictive value of 91% 
(688/758).
Discussion
With increasing interest in eosinophilic esophagitis in recent years, the finding of 
eosinophilia on esophageal biopsy is being more frequently encountered. However, the 
spectrum of esophageal eosinophilia has not previously been well described and the 
variability in this finding had yet to be fully quantified. In this study of prospectively 
obtained esophageal biopsy specimens, histologic findings related to esophageal 
eosinophilia were analyzed in order to determine the distribution and variability of 
esophageal eosinophilia in subjects undergoing endoscopy.
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Our study had several key findings. First, the large majority of patients undergoing upper 
endoscopy had little to no esophageal eosinophilia regardless of whether the analysis was at 
the per patient, per biopsy, or per hpf level. This solidifies the concept that having an 
eosinophilic infiltrate in the esophagus is abnormal. Second, patients with eosinophilic 
esophagitis not only had high levels of esophageal eosinophilia, but had marked variability 
in the eosinophil counts on both the per biopsy and per hpf level. This implies that multiple 
biopsies from multiple locations need to be obtained, and that multiple hpfs must be 
examined on each biopsy. Finally, we provide quantifiable prospective data about the 
distribution of eosinophils in eosinophilic esophagitis cases compared with subjects without 
eosinophilic esophagitis, and provide the first evidence-based support for the 15 eos/hpf cut 
point for diagnosis of eosinophilic esophagitis.
The variability of the eosinophilic infiltrate in eosinophilic esophagitis has been described 
before, but these descriptions have largely been limited to cohorts of eosinophilic 
esophagitis patients, either in sub-analyses from clinical trials18-21 or in retrospective 
studies,15,22 without a non- eosinophilic esophagitis comparator group for context. In these 
latter two studies, the authors determined that obtaining a total of five biopsies yielded a 
diagnostic sensitivity of 100% for eosinophilic esophagitis with a histologic cut-point of 15 
eos/hpf.15,22 A unique analysis of an esophagectomy specimen from a patient with 
eosinophilic esophagitis was able to explicitly show the variability in eosinophilia.23 This 
study found that just 31.5% of hpfs (a total of 1215 were examined from this single patient) 
had an eosinophil count ≥ 15 eos/hpf, a finding that is very similar to what we present here 
for our entire patient population on the per-hpf analysis. The same group has also presented 
preliminary data on 6 patients undergoing a strict and extensive esophageal biopsy 
protocol.24 This suggested that up to 17 biopsies might be required to find high levels of 
esophageal eosinophilia, with fewer in areas with endoscopic findings such as white plaques 
and more from areas of normal-appearing esophageal mucosa. An additional retrospective 
study of an eosinophilic esophagitis cohort performed a per-biopsy analysis of 1342 
fragments and concluded that obtaining at least 4 biopsy specimens would provide a 
diagnostic yield of >99% with a 15 eos/hpf cut-point.25 Our biopsy protocol obtained 
random biopsies from the distal, mid, and proximal esophagus, and while there was a large 
variation in eosinophil counts between hpfs within biopsies, for the eosinophilic esophagitis 
cases 63% of biopsies had at least 1 hpf with ≥ 15 eos/hpf. This result is consistent with 
these prior studies and lends support to the current guidelines recommendation of obtaining 
2-4 biopsies from at least 2 locations in the esophagus to obtain adequate tissue for 
eosinophilic esophagitis diagnosis.
Because these prior studies are nested within eosinophilic esophagitis cohorts, they are 
unable to assess the utility of the level of 15 eos/hpf as a diagnostic cut-point. This cut point 
was originally recommended in the first iteration of the eosinophilic esophagitis clinical 
guidelines4 to attempt to bring a measure of uniformity to variable case definitions in the 
literature.14 While based on data showing that that lower levels of eosinophilic infiltration in 
the esophagus was often due to gastroesophageal reflux disease,26,27 there has been little 
empiric data to support this recommendation.28,29 Our study is the first of which we are 
aware to prospectively enroll patients undergoing endoscopy and review biopsies from both 
cases of eosinophilic esophagitis and subjects without eosinophilic esophagitis to determine 
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the utility of the 15 eos/hpf cut-point. We found that this cut point has an excellent 
sensitivity, specificity, and negative predictive value for diagnosis of eosinophilic 
esophagitis, and performs better than alternative cut-points such as 10 or 20 eos/hpf. These 
findings also support current diagnostic recommendations.6,7
It is important to acknowledge the limitations and strengths of this study. First, it is a single 
center study at an esophageal referral center, but the characteristics of the eosinophilic 
esophagitis cases are similar to those reported in multiple other studies.15,30-33 Second, this 
study only enrolled adults, so it is unknown if the current results would be applicable to 
children. Third, it is important to note that the eosinophil counts presented in this study for 
subjects with eosinophilic esophagitis and proton pump inhibitor-responsive esophageal 
eosinophilia were measured after therapy with a proton pump inhibitor, so while patients 
with proton pump inhibitor-responsive esophageal eosinophilia are included, their samples 
are categorized with the non- eosinophilic esophagitis cases. We are therefore unable to 
comment on variability in eosinophil counts in patients with proton pump inhibitor-
responsive esophageal eosinophilia prior to the proton pump inhibitor trial. We feel that the 
strengths of this study, including its prospective design, comprehensive and standardized 
histopathologic analysis using a previously validated and reproducible protocol, and ability 
to compare eosinophilic esophagitis cases to non- eosinophilic esophagitis controls, 
outweigh the potential limitations.
In conclusion, this study of the spectrum of esophageal eosinophilia in patients undergoing 
upper endoscopy and biopsy found that most patients have little to no esophageal 
eosinophilia, but that levels of esophageal eosinophilia in patients with eosinophilic 
esophagitis varies tremendously on per patient, per biopsy, and per hpf analyses. Because 
nearly two-thirds of biopsies had at least 15 eos/hpf, obtaining at least 3 biopsies may 
provide adequate diagnostic yield, but the marked variability implies that when more 
biopsies are obtained, the sensitivity of diagnosis increases. Because approximately only 
one-third of hpfs had at least 15 eos/hpf, examining multiple hpfs per biopsy speciem is also 
important. In addition, these data support the current histologic cut-point of 15 eos/hpf for 
diagnosis of eosinophilic esophagitis. Data from this study can be used to make biopsy-
related recommendations in future iterations of eosinophilic esophagitis guidelines, and may 
be helpful for biopsy acquisition and histologic assessment protocols in clinic trial design.
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Histograms of the distribution of esophageal eosinophilia (eos/hpf) in patients undergoing 
upper endoscopy. (A) Histogram for the per-patient analysis. (B) Histogram for the per-
biopsy analysis. (C) Histogram for the per-hpf analysis.
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Distribution of esophageal eosinophilia in patients with eosinophilic esophagitis, stratified 
by biopsy location. (A) Distribution for the per-biopsy analysis. (B) Distribution for the per-
hpf analysis. The dark gray represents proximal locations, the light gray is midesophagus, 
and the black represents distal locations.
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Table 1
Characteristics of the study population
Total population
(n = 213)
Age (mean ± SD) 49.2 ± 15.4
Male (n, %) 102 (48)
White (n, %) 173 (81)
Symptoms/upper endoscopy indication (n, %)
 Dysphagia 165 (77)
 Heartburn 30 (14)
 Abdominal pain 23 (11)
 Nausea/vomiting 6 (3)
Upper endoscopy findings (n, %)
 Normal 37 (17)
 Rings 74 (35)
 Stricture 47 (22)
 Narrowing 27 (13)
 Furrows 61 (29)
 Crêpe-paper 4 (2)
 White plaques/exudates 35 (16)
 Decreased vascularity 17 (8)
 Erosive esophagitis 34 (16)
 Schatzki’s ring 17 (8)
 Hiatal hernia 58 (27)
 Dilation performed 68 (32)




 Eosinophilic esophagitis 41 (19)
 Proton pump inhibitor-responsive esophageal
  eosinophilia
24 (11)
 Control 148 (70)
  Normal 11 (5)
  Reflux 45 (21)
  Peptic stricture 10 (5)
  Non-peptic stricture 9 (4)
  Schatzki’s ring 11 (5)
  Achalasia 9 (4)
  Non-achalasia esophageal dysmotility 16 (7)
  Functional esophageal disorders 6 (3)
  Other 31 (11)
*
By definition, all of the eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia cases were on a proton pump 
inhibitor at endoscopy; 103 of the other subjects (70%) were on a proton pump inhibitor at the discretion of their referring physician at the time of 
endoscopy.
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Table 2







≥ 15 eos/hpf (n, %) 48 (23) 165 (18) 449 (10)
Max eosinophil count
 (mean eos/hpf ± SD, range)
24.6 ± 64.9 (0-466) 13.2 ± 40.9 (0-466) 6.6 ± 25.9 (0-466)
Max eosinophil count
 (median eos/hpf, IQR)
1.5 (0-14) 0 (0-6.2) 0 (0-1.4)
Degranulation (n, %) 71 (33) 218 (24) 645 (14)
Microabscess (n, %) 27 (13) 60 (7) 136 (3)
Basal layer evaluable (n, %) 212 (99) 876 (95) --
Basal hyperplasia (n, %) 48 (23) 102 (12) --
 25-50% high 25 (12) 55 (6)
 50-75% high 23 (11) 47 (5)
Spongiosis (n, %) 60 (28) 153 (17) --
Subepithelial stroma present (n, %) 81 (38) 151 (16) --
Lamina prop fibrosis (n, %) 16 (8) 26 (3) --
Mucosal distribution (n, %)* -- --
 Basal 39 (14)
 Superficial 50 (19)
 Diffuse 181 (67)
Biopsy distribution (n, %)* -- --
 Patchy 216 (67)
 Diffuse 109 (33)
*
Percentages are calculated for those biopsies where there are eosinophils present and the distribution of eosinophils can be assessed
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